GlaxoSmithKline: Mental Disorders trials
The registry lists 10 Mental Disorders studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 4Phase 2 2Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Open-label Extension Study in Participants With Early Alzheimer's DiseaseRecruitingNCT07105709Phase 2
- Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseaseTerminatedNCT06079190Phase 2
- Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With PlaceboCompletedNCT01607086Phase 1
- A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy SmokersCompletedNCT01371799Phase 1
- Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)CompletedNCT01371461
- Special Drug Use Investigation for PAXIL Tablet (Long-term)CompletedNCT01371448
- Drug Use Investigation for PAXIL TabletCompletedNCT01371435
- Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy VolunteersCompletedNCT00449774Phase 1
- Study to Compare Two Formulations of Lamotrigine in Healthy SubjectsCompletedNCT00410371Phase 1
- Combination Of PAXIL Tablet And BenzodiazepinesCompletedNCT00259883Phase 4